The trademark application was filed by Theriva Biologics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on September 10, 2023, and it was registered by office on December 18, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for the treatment, prevention and alleviation of gastrointestinal diseases, infections, dysbiosis, and disorders
Pharmaceutical preparations for the treatment of metabolic diseases and disorders
Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal health, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for gastrointestinal dysbiosis, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for systemic illnesses associated with gastrointestinal dysbiosis, gastrointestinal disorders, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for systemic illnesses associated with gastrointestinal disorders, gastrointestinal diseases, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for systemic illnesses associated with gastrointestinal diseases, gastrointestinal infections, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceuticals, namely, pharmaceutical preparations for systemic illnesses associated with gastrointestinal infections, used to maintain health and restore health to a human or animal subject via treatment of a disturbed microbial community and prevention of microbial community disruption
Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors
Oncolytic viral therapies
Biological therapies for use in the treatment of cancer and tumors.